Analytical evaluation of a second generation assay for chromogranin A; a dual-site study

Krabbe, Johannes G.; Monaghan, Phillip J.; Russell, Joanne; Rijke, Yolanda B. de

doi:10.1515/cclm-2015-0782

Cited by 7 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chromogranin A and NSE levels were measured on the fully automated B·R·A·H·M·S KRYPTOR ® instrument (Thermo Fisher Scientific, Hennigsdorf/Berlin, Germany) as described previously [21]. Total PSA level was measured with the B·R·A·H·M·S KRYPTOR analyser retrospectively in the DOC and the ABI/ENZA cohorts, while in the RP cohort the endpoint of PSA progression (Table S1) was assessed according to total PSA measured with the ARCHITECT analyser (Abbott Laboratories, Lake Forest, IL, USA) during clinical routine.…”

Section: Methodsmentioning

confidence: 99%

Comprehensive analysis of serum chromogranin A and neuron‐specific enolase levels in localized and castration‐resistant prostate cancer

et al. 2020

View full text Add to dashboard Cite

To assess chromogranin A (CGA) and neuron-specific enolase (NSE) levels and changes in these at different stages of prostatic adenocarcinoma (PCA). Methods Overall, 1095 serum samples from 395 patients, divided into three treatment groups, were analysed; the radical prostatectomy (RP) cohort (n = 157) included patients with clinically localized PCA, while the docetaxel (DOC) and the abiraterone (ABI)/enzalutamide (ENZA) cohorts included 95 and 143 patients, respectively, with metastatic castration-resistant prostate cancer. CGA, NSE and total PSA levels were measured using the KRYPTOR method. Results Baseline CGA and NSE levels were higher in castration-resistant (DOC and ABI/ENZA cohorts) than in hormone-na€ ıve, clinically localized PCA (P < 0.001). High baseline CGA levels were independently associated with poor overall survival in both the DOC and the ABI/ENZA cohorts, with a stronger association in the ABI/ENZA cohort. In the ABI/ENZA cohort, a > 50% CGA increase at 3 months was associated with poor survival, especially in patients with high baseline CGA levels. Conclusions The two-to threefold higher neuroendocrine marker levels in castration-resistant compared to hormone-na€ ıve PCA support the presence of neuroendocrine transdifferentiation under androgen deprivation therapy. Our results showed patients with high baseline CGA levels who experienced a further CGA increase during ABI and ENZA treatment had the poorest prognosis. Serum CGA levels could help in tailoring and monitoring therapy in advanced PCA.

show abstract

Section: Methodsmentioning

confidence: 99%

Comprehensive analysis of serum chromogranin A and neuron‐specific enolase levels in localized and castration‐resistant prostate cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This study provides evidence that measurement of CgA alone is sufficient in the management of patients with NETs and that routine additional measurement of CgB provides little added value. By enabling a reorganization of assay provision and set‐up within a routine service laboratory, the adoption of first‐line CgA‐only testing using a commercially available automated assay for on‐site measurement has permitted quality improvements reflected in key performance indicators, including turnaround time of test results, continued professional development for laboratory professionals, and enhancing the laboratory repertoire for specialist oncology assay service provision.…”

Section: Discussionmentioning

confidence: 99%

Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours

Monaghan

Lamarca

Valle

et al. 2015

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…CGA levels were measured on the fully automated B.R.A.H.M.S KRYPTOR instrument (Thermo Scientific B.R.A.H.M.S GmbH, Hennigsdorf/Berlin, Germany) using the B.R.A.H.M.S. CGA II homogeneous sandwich fluoroimmuno-assay as described previously (20, 21, 22). The functional sensitivity of this assay is 13.7 ng/mL.…”

Section: Methodsmentioning

confidence: 99%

High-soluble CGA levels are associated with poor survival in bladder cancer

Szarvas

Jardin-Watelet²,

Bourgoin³

et al. 2019

Endocrine Connections

View full text Add to dashboard Cite

Recently, a neuroendocrine-like molecular subtype has been discovered in muscle-invasive urothelial bladder cancer (BC). Chromogranin A (CGA) is a widely used tissue and serum marker in neuroendocrine tumors. Our aim was to evaluate serum CGA (sCGA) concentrations and their associations with clinical and follow-up data in BC and renal cell carcinoma (RCC). sCGA concentrations were analyzed in the following cohorts: (1) BC training set (n = 188), (2) BC validation set (n = 125), (3) RCC patients (n = 77), (4) healthy controls (n = 97). CGA immunohistochemistry and RT-qPCR analyses were performed in 20 selected FFPE and 29 frozen BC tissue samples. Acquired data were correlated with clinicopathological parameters including comorbidities with known effect on sCGA as well as with patients’ follow-up data. sCGA levels were significantly higher in BC but not in RCC patients compared to healthy controls. High sCGA levels were independently associated with poor overall and disease-specific survival both in the BC training (P < 0.001, P = 0.002) and validation set (P = 0.009, P = 0.017). sCGA levels were inversely correlated with glomerulus filtrating rate (GFR) and linearly correlated with creatinine clearance and urea concentrations. These correlations were not related to the prognostic value of sCGA. Tissue CGA levels were low to absent independently of sCGA concentrations. Our results demonstrate elevated levels and an independent prognostic value for sCGA in BC but not in RCC. Despite the significant correlation between sCGA and GFR, the prognostic relevance of sCGA seems not related to impaired renal function or other comorbidities.

show abstract

Analytical evaluation of a second generation assay for chromogranin A; a dual-site study

Cited by 7 publications

References 4 publications

Comprehensive analysis of serum chromogranin A and neuron‐specific enolase levels in localized and castration‐resistant prostate cancer

Comprehensive analysis of serum chromogranin A and neuron‐specific enolase levels in localized and castration‐resistant prostate cancer

Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours

High-soluble CGA levels are associated with poor survival in bladder cancer

Contact Info

Product

Resources

About